Eyepoint Pharmaceuticals, Inc.
Clinical trials sponsored by Eyepoint Pharmaceuticals, Inc., explained in plain language.
Develops ophthalmic therapies for eye diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New eye drug could mean fewer shots for Diabetes-Related vision loss
Disease control Recruiting nowThis study tests a new medicine, EYP-1901, given as an eye injection to people with diabetic macular edema (DME), a condition that causes blurry vision in people with diabetes. The goal is to see if EYP-1901 works as well as the standard treatment (aflibercept) but with fewer inj…
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New eye drug could cut injection frequency for Diabetes-Related vision loss
Disease control Recruiting nowThis phase 3 trial tests EYP-1901, a new eye injection, against the standard treatment aflibercept for diabetic macular edema (DME), a condition that causes vision loss in people with diabetes. The study will enroll 240 participants and compare how well each drug improves vision …
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC